超越子宫收缩乏力:产后出血凝血功能障碍的特征分析
这项前瞻性研究在单中心城市医院纳入81例患者(66例产后出血,15例对照),发现产后出血患者纤维蛋白原水平降低、纤溶抵抗增加、凝血酶生成峰值和最大速率降低,且组织因子水平降低、组织因子途径抑制物水平升高、组织因子途径抑制物比值降低。结论认为产后出血不仅是子宫张力和机械性出血问题,还是一种以低纤维蛋白原、血凝块降解抵抗和凝血酶生成显著降低为特征的凝血功能障碍。
要点
- 产后出血患者纤维蛋白原水平显著低于无产后出血者(469.0 mg/dL vs 411.0 mg/dL,P=.02)。
- 产后出血患者凝血酶生成峰值浓度和最大速率均显著降低(150.2 nM vs 40.7 nM;60.1 nM/分钟 vs 2.8 nM/分钟)。
- 产后出血患者组织因子水平降低而组织因子途径抑制物水平升高,组织因子途径抑制物比值降低(624 vs 299,P=.01)。
核心结论
- 产后出血不仅是子宫张力和机械性出血问题,还是一种以纤维蛋白原水平降低、血凝块降解抵抗和凝血酶生成显著降低为特征的凝血功能障碍。
- 该病理似乎由低组织因子水平和高组织因子途径抑制物水平驱动。
研究设计与样本
- 前瞻性研究,在单中心城市医院完成,纳入妊娠患者。
- 共纳入81例患者,其中66例产后出血,15例为对照。
- 在诊断为产后出血时以及之后2小时和4小时采血。
- 产后出血患者检测包括血栓弹力图、全血凝血酶生成、凝血因子活性、组织因子水平和活性、组织因子途径抑制物水平,并与无产后出血患者比较。
主要发现
- 与无产后出血患者相比,产后出血患者纤维蛋白原水平更低(469.0 mg/dL vs 411.0 mg/dL;P=.02)。
- 与无产后出血患者相比,产后出血患者组织型纤溶酶原激活物抵抗增加(最大血凝块强度后30分钟纤溶:8.7% vs 4.2%;P=.02)。
- 与无产后出血患者相比,产后出血患者凝血酶生成峰值浓度降低(150.2 nM vs 40.7 nM;P=.01),凝血酶生成最大速率降低(60.1 nM/分钟 vs 2.8 nM/分钟;P=.02)。
- 与无产后出血患者相比,产后出血患者组织因子水平降低(444.3 pg/mL vs 267.1 pg/mL;P=.02),组织因子途径抑制物水平升高(0.6 U/mL vs 0.8 U/mL;P=.04),组织因子途径抑制物比值降低(624 vs 299;P=.01)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Postpartum hemorrhage is a leading cause of morbidity and mortality worldwide, yet the associated early coagulopathy is not well defined. OBJECTIVE: We hypothesized that women who develop postpartum hemorrhage have a distinct derangement of thrombin generation and coagulation factors compared with postpartum women without postpartum hemorrhage. STUDY DESIGN: This prospective study of pregnant patients with postpartum hemorrhage was completed at a single urban hospital. Blood was drawn on postpartum hemorrhage diagnosis and 2 and 4 hours later. Assays of patients with postpartum hemorrhage included thrombelastography, whole blood thrombin generation, coagulation factor activity, tissue factor levels and activity, and tissue factor pathway inhibitor levels, which were compared with that of patients without postpartum hemorrhage. RESULTS: A total of 81 patients were included in this study. Of those patients, 66 had postpartum hemorrhage, and 15 served as controls. Compared with patients without PPH, patients with postpartum hemorrhage had lower fibrinogen levels (469.0 mg/dL vs 411.0 mg/dL; P=.02), increased tissue plasminogen activator resistance (fibrinolysis 30 minutes after maximal clot strength: 8.7% vs 4.2%; P=.02), decreased peak thrombin concentration (150.2 nM vs 40.7 nM; P=.01), and decreased maximal rate of thrombin generation (60.1 nM/minute vs 2.8 nM/minute; P=.02). Furthermore, compared with patients without postpartum hemorrhage, patients with postpartum hemorrhage had decreased tissue factor levels (444.3 pg/mL vs 267.1 pg/mL; P=.02) and increased tissue factor pathway inhibitor levels (0.6 U/mL vs 0.8 U/mL; P=.04), with decreased tissue factor pathway inhibitor ratios (624 vs 299; P=.01). CONCLUSION: PPH is not only an issue of uterine tone and mechanical bleeding but also a distinct coagulopathy that is characterized by decreased fibrinogen level, clot breakdown resistance, and markedly low thrombin generation. This pathology seemed to be driven by low tissue factor and high tissue factor pathway inhibitor levels.
引用
- Coleman JR, Fabbri S, Anderson M, et al. Beyond uterine atony: characterizing postpartum hemorrhage coagulopathy. Am J Obstet Gynecol MFM. 2022. PMID: 36464240. doi:10.1016/j.ajogmf.2022.100822
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。